BIOLASE (BIOL) Competitors

BIOLASE (NASDAQ:BIOL) and NAYA Biosciences (NASDAQ:NAYA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.

Does the media favor BIOL or NAYA?

In the previous week, BIOLASE had 1 more articles in the media than NAYA Biosciences. MarketBeat recorded 1 mentions for BIOLASE and 0 mentions for NAYA Biosciences. BIOLASE's average media sentiment score of 0.00 equaled NAYA Biosciences'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
NAYA Biosciences	Neutral

Do analysts rate BIOL or NAYA?

BIOLASE currently has a consensus price target of $1.20, suggesting a potential upside of 11,550.49%. NAYA Biosciences has a consensus price target of $24.00, suggesting a potential upside of 1,000.92%. Given BIOLASE's higher probable upside, research analysts plainly believe BIOLASE is more favorable than NAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
NAYA Biosciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher earnings & valuation, BIOL or NAYA?

NAYA Biosciences has lower revenue, but higher earnings than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.01	-$20.63M	-$14.94	0.00
NAYA Biosciences	$6.23M	0.23	-$8.03M	N/A	N/A

Do institutionals & insiders have more ownership in BIOL or NAYA?

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 12.0% of NAYA Biosciences shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 1.8% of NAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is BIOL or NAYA more profitable?

BIOLASE has a net margin of -41.65% compared to NAYA Biosciences' net margin of -119.91%. NAYA Biosciences' return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
NAYA Biosciences	-119.91%	N/A	-41.72%

Which has more volatility and risk, BIOL or NAYA?

BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, NAYA Biosciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Does the MarketBeat Community believe in BIOL or NAYA?

BIOLASE received 291 more outperform votes than NAYA Biosciences when rated by MarketBeat users. However, 100.00% of users gave NAYA Biosciences an outperform vote while only 51.05% of users gave BIOLASE an outperform vote.

Company	Underperform	Outperform
BIOLASE	Outperform Votes 292 51.05%	Underperform Votes 280 48.95%
NAYA Biosciences	Outperform Votes 1 100.00%	Underperform Votes No Votes

Summary

NAYA Biosciences beats BIOLASE on 9 of the 15 factors compared between the two stocks.